Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Clin Cancer Res. 2014 Apr 29;20(13):3521–3530. doi: 10.1158/1078-0432.CCR-14-0395

Fig. 3. In vitro potency determinations for amoxapine and its metabolites.

Fig. 3

IC50 values provided in the tables are average values based on three independent determinations along with standard deviations (SD). (A) IC50 value determinations were performed for amoxapine (■), 7-OH amoxapine (▲) and 8-OH amoxapine (▼) using the GUS enzyme assay. The indicated concentrations were tested in duplicate and activity was normalized to control wells (± enzyme). (B) IC50 value determinations were performed for amoxapine (■), 7-OH amoxapine (▲) and 8-OH amoxapine (▼) using the bacterial cell-based GUS activity assay. The indicated concentrations were tested in duplicate and activity was normalized to control wells (± bacteria). (C) The indicated compounds were tested in the bacterial cytotoxicity assay at 20 and 2 μM, as indicated. The compounds were tested in triplicate at these concentrations and activity was normalized to control wells (± bacteria). The antibiotic kanamycin (Kan) was included as a positive control. Data points represent the average of two or three determinations per variable and error bars represent SD. Data shown are representative of three independent experiments.